Listando por materia "Ephrin type-A receptor 2"

Mostrando ítems 1-1 de 1

FDA-approved antivirals ledipasvir and daclatasvir downregulate the Src-EPHA2-Akt oncogenic pathway in colorectal and triple-negative breast cancer cells

Mezquita, Betlem; Reyes-Farias, Marjorie; Pons, Miquel (Elsevier, 2024)

Direct-acting antivirals ledipasvir (LDV) and daclatasvir (DCV) are widely used as part of combination therapies to treat Hepatitis C infections. Here we show that these compounds inhibit the proliferation, ...